Silencing of LINC01116 Suppresses the Development of Oral Squamous Cell Carcinoma by up-Regulating microRNA-136 to Inhibit FN1 [Retraction]


The Editor and Publisher of Cancer Management and Research wish to retract the published article. Concerns were raised regarding the alleged duplication of regions found in images from Figure 7 and Figure 9. Specifically,

- Figure 7A, panel 48 h Blank appears to show duplicated regions.
- Figure 7A, panel 48 h NC appears to show duplicated regions.
- Figure 7A, panel 48 h siRNA-LINC01116 appears to show duplicated regions.
- Figure 7A, panel 48 h miR-136 inhibitor appears to show duplicated regions.
- Figure 7A, panel 48 h siRNA-LINC01116 + miR-136 inhibitor appears to show duplicated regions.
- Figure 7B, panel Blank and siRNA-LINC01116 + miR-136 inhibitor appears to show duplicated regions.
- Figure 7B, panel Blank and siRNA-LINC01116 + miR-136 inhibitor appears to show duplicated regions.
- Figure 7B, panel Blank and siRNA-LINC01116 + miR-136 inhibitor appears to show duplicated regions.
- Figure 7B, panel Blank and siRNA-LINC01116 + miR-136 inhibitor appears to show duplicated regions.
- Figure 9C, panel TSCCa siRNA-LINC01116 appears to show duplicated regions.
- Figure 9C, panel TSCCa siRNA-LINC01116 appears to show duplicated regions.
- Figure 9C, panel TSCCa miR-136 mimic appears to show duplicated regions.
- Figure 9C, panel TSCCa miR-136 inhibitor appears to show duplicated regions.
- Figure 9C, panel Tca83 miR-136 mimic appears to show duplicated regions.
- Figure 9C, panel Tca83 miR-136 inhibitor appears to show duplicated regions.
- Figure 9C, panel Tca83 siRNA-LINC01116 + miR-136 inhibitor appears to show duplicated regions.

The authors responded to our queries but were unable to provide a satisfactory explanation for the alleged duplication nor were they able to provide adequate original data for their study. The Editor requested to retract the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Cancer Management and Research

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal

Dovepress

© 2022 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporates the Creative Commons Attribution – Non Commercial (unported, v3.0) License (https://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).